Chinese bulk aspirin
This article was originally published in The Tan Sheet
Executive Summary
Shandong Xinhua Pharmaceutical did not make bulk aspirin sales "below normal value" from July 1, 2002 through June 30, 2003, the International Trade Administration says April 8. ITA therefore preliminarily finds that an antidumping order for the Chinese firm should be revoked, and invites comment before publication of final notice. The Department of Commerce originally published an antidumping order on Shandong Xinhua bulk aspirin in July 2000 (1"The Tan Sheet" July 3, 2000, p. 2)...
You may also be interested in...
Aspirin dumping
U.S. Customs service will impose antidumping duties on bulk aspirin imports from China following a June 22 ITC determination the imports threaten U.S. industry with material injury. In an amended final determination June 21, the ITA revises previously announced weighted-average dumping margins for two Chinese firms: Shandong Xinhua Pharmaceutical Factory, 16.5% (previously 42.8%) and Jilin Pharmaceutical, 10.9% (previously 4.7%). The PRC-wide rate of 144% is unchanged (1"The Tan Sheet" May 29, In Brief)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.